Study authors assessed whether azithromycin in addition to a hydroxychloroquine regimen shows positive results in clinical improvement or mortality reduction in patients hospitalized with severe COVID-19.
The global burden of musculoskeletal disorders is considerable, but prevalence and DALYs have decreased slightly since 1990.
The COVID-19 Global Rheumatology Alliance Patient Experience Survey was used to assess the effect of antimalarial drug shortages during the COVID-19 pandemic.
Neurologic disturbances in patients with coronavirus disease 2019 were accompanied by evidence of cytokine release syndrome.
Clinicians should use caution when interpreting the guidelines for the diagnosis and detection of sarcoidosis and must consider unique individual clinical circumstances when managing these patients.
Tocilizumab may be beneficial for adults with COVID-19 admitted to the ICU although other findings are conflicting.
Cytokine levels in severely, critically ill COVID-19 patients are much lower than in other inflammatory syndromes.
In this episode, we discuss how the the microbiome can play a role in the potential treatment of rheumatic diseases.
In patients with sarcoidosis, cancer was found to develop earlier in men vs women.
Genetic variants mimicking therapeutic inhibition of the IL-6 receptor may be associated with lower hospitalization risk in COVID-19.
